Detrusor overactivity—an update
2004; Wiley; Volume: 111; Issue: s1 Linguagem: Inglês
10.1111/j.1471-0528.2004.00468.x
ISSN1471-0528
AutoresPhilip Toozs‐Hobson, A. Elnaqa,
Tópico(s)Urological Disorders and Treatments
ResumoBJOG: An International Journal of Obstetrics & GynaecologyVolume 111, Issue s1 p. 53-56 Detrusor overactivity—an update P. Toozs-Hobson, P. Toozs-Hobson Birmingham Women's Hospital, Birmingham, UKSearch for more papers by this authorA. Elnaqa, A. Elnaqa Birmingham Women's Hospital, Birmingham, UKSearch for more papers by this author P. Toozs-Hobson, P. Toozs-Hobson Birmingham Women's Hospital, Birmingham, UKSearch for more papers by this authorA. Elnaqa, A. Elnaqa Birmingham Women's Hospital, Birmingham, UKSearch for more papers by this author First published: 01 December 2004 https://doi.org/10.1111/j.1471-0528.2004.00468.xCitations: 4 Dr P. Toozs-Hobson, Birmingham Women's Hospital, Birmingham, UK. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Andersson K-E. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev 1993; 45: 253. PubMedWeb of Science®Google Scholar 2 Anderson K-E, Yoshida M. Antimuscarinics and the overactive bladder — which is the main mechanism of action? Eurpoean Urol 2003; 1: 1–5.DOI: 10.1016/S0302-2838(02)00540-7 10.1016/S0302-2838(02)00540-7 Web of Science®Google Scholar 3 Cardozo LD, Cooper D, Versi E. Oxybutynin chloride in the management of idiopathic detrusor instability. BMJ 1987; 280: 281–282. 10.1136/bmj.280.6210.281 PubMedWeb of Science®Google Scholar 4 Birns J, Malone-Lee JG, and the oxybutynin CR Study Group. Controlled-release oxybutynin maintains efficacy with a 43% reduction in side effects compared to conventional treatment. Neurourol Urodyn 1997; 16: 429–430. Google Scholar 5 Dmchowski R, Staskin D, Appell R, et al. The efficacy, effectiveness, and safety of transdermal oxybutynin in patients with overactive bladder. Neurourol Urodyn 2003; 22: 533–534. Google Scholar 6 Abrams P, Freeman RM, Anderstrom C, Mattiasson A. Efficacy and tolerability of tolterodine vs oxybutynin and placebo in patients with detrusor instability. Br J Urol 1998; 81: 801–810.DOI: 10.1046/j.1464-410X.1998.00717.x 10.1046/j.1464-410X.1998.00717.x CASPubMedWeb of Science®Google Scholar 7 Van Kerrebroeck PEVA, Serment G, Dreher E. Clinical efficacy and safety of tolterodine compared to oxybutynin in patients with overactive bladder. Neurourol Urodyn 1997; 16: 478–479. Google Scholar 8 Rudy D, Cline K, Goldberg K, Harris R. A multicenter randomized, placebo controlled trial of trospium chloride in overactive bladder patients. Neuurol Urodyn 2004; 23: 600–601. CASWeb of Science®Google Scholar 9 Juenemann K, Hessdoerfer E, Unamba-Oparah I, et al. Propiverine Hydrochloride immediate (IR) and extended release (ER): comparison of efficacy and tolerability in patients with overactive bladder. Neurourol Urodyn 2004; 23: 599–600. CASWeb of Science®Google Scholar 10 Chapple C, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Ridder A. Results of a randomized phase 3 study comparing solifenacin succinate with tolterodine and placebo in patients with symptomatic overactive bladder. Neurourol Urodyn 2003; 22: 534–535. Google Scholar 11 Hill S, Khullar V. Darifenacin, a muscarinic receptor antagonist with selectivity for M3 receptors, reduces incontinence and nocturia in patients with overactive bladder. Neurourol Urodyn 2004; 23: 602–603. CASWeb of Science®Google Scholar 12 Herbison P, Hay-Smith J, Moore K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 2003; 326: 841–844. 10.1136/bmj.326.7394.841 CASPubMedWeb of Science®Google Scholar 13 Wilson D. Nonsurgical management of incontinence. In: AB Maclean, LD Cardozo, editors. Incontinence in Women. RCOG Press, 2002 Chapter 16. Google Scholar 14 Robinson D, Cardozo L, Akeson M, Hvistendhal G, Riis A, Norgaard JP. Anti-diuresis—for the control of daytime incontinence. Int Urogynecol J 2002; 13: S6. Web of Science®Google Scholar 15 Leippold T, Reitz A, Schurch B. Botulinum toxin as a new therapy for voiding disorders: current state of the art. Eur Urol 2003; 44: 165–174.DOI: 10.1016/S0302-2838(03)00250-1 10.1016/S0302-2838(03)00250-1 CASPubMedWeb of Science®Google Scholar Citing Literature Volume111, Issues1December 2004Pages 53-56 ReferencesRelatedInformation
Referência(s)